Explore

TrendlineTrendline
Janux Therapeutics Initiates Phase 1 Study for JANX013 in Metastatic Prostate Cancer

Janux Therapeutics Initiates Phase 1 Study for JANX013 in Metastatic Prostate Cancer

Janux Therapeutics Initiates Phase 1 Study for JANX013 in Metastatic Prostate Cancer
TrendlineTrendline
Shennon Biotechnologies Raises $12 Million in Financing, Appoints New CEO, and Unveils Precision Immunotherapy Pipeline

Shennon Biotechnologies Raises $12 Million in Financing, Appoints New CEO, and Unveils Precision Immunotherapy Pipeline

Shennon Biotechnologies Raises $12 Million in Financing, Appoints New CEO, and Unveils Precision Immunotherapy Pipeline
Rapid ReadRapid Read
BostonGene Expands AI-Powered Collaboration with Dana-Farber Cancer Institute for Breast Cancer Research

BostonGene Expands AI-Powered Collaboration with Dana-Farber Cancer Institute for Breast Cancer Research

BostonGene, a developer of AI models for tumor and immune biology, has expanded its scientific collaboration with the Dana-Farber Cancer Institute. This expanded partnership aims to deepen the understanding of the complex biological mechanisms driving BRCA1- and BRCA2-associated breast cancers. The collaboration will utilize BostonGene's foundation model of tumor and immune biology and multimodal AI analytics to place individual tumors within a broader biological context. This approach seeks to systematically discover mechanisms that differentiate disease subtypes, drive therapeutic response, and contribute to resistance. The research will focus on BRCA1/2-associated ER-positive breast cancer (BRCA ER+), TP53-mutant ER-positive breast cancer (TP53 ER+), and triple-negative breast cancer (TNBC).
TrendlineTrendline
TwoStep Therapeutics Secures $62.5 Million Series A Funding and FDA Clearance for Cancer Drug

TwoStep Therapeutics Secures $62.5 Million Series A Funding and FDA Clearance for Cancer Drug

TwoStep Therapeutics Secures $62.5 Million Series A Funding and FDA Clearance for Cancer Drug
TrendlineTrendline
QurCan Therapeutics and Lilly Partner to Advance Nucleic Acid Therapies for Neurological Diseases

QurCan Therapeutics and Lilly Partner to Advance Nucleic Acid Therapies for Neurological Diseases

QurCan Therapeutics and Lilly Partner to Advance Nucleic Acid Therapies for Neurological Diseases
Rapid ReadRapid Read
Yarrow Bioscience Closes $172.5 Million Public Offering to Advance Autoimmune Thyroid Therapies

Yarrow Bioscience Closes $172.5 Million Public Offering to Advance Autoimmune Thyroid Therapies

Yarrow Bioscience, Inc. (Nasdaq: YARW), a clinical-stage biotechnology company, has successfully closed its underwritten public offering, raising approximately $172.5 million in gross proceeds. The offering included the full exercise of the underwriters’ option to purchase additional shares, totaling 6,634,615 shares of common stock at a public offering price of $26.00 per share. Yarrow Bioscience specializes in developing transformative therapies for autoimmune thyroid diseases. The company intends to allocate the net proceeds from this offering primarily to fund research and development expenses for its pipeline, as well as for general corporate purposes, including working capital and capital expenditures. Jefferies, TD Cowen, and Guggenheim Securities acted as joint book-running managers for the offering, with LifeSci Capital serving as lead manager.
Rapid ReadRapid Read
Elvinix Licenses Peptide Therapy from Zealand Pharma to Restore Insulin Production in Type 1 Diabetes

Elvinix Licenses Peptide Therapy from Zealand Pharma to Restore Insulin Production in Type 1 Diabetes

Elvinix Inc., a biopharmaceutical company based in Dover, Delaware, has secured an exclusive license agreement with Zealand Pharma A/S to develop and commercialize Zealand’s GLP-1/gastrin dual-agonist peptide portfolio. This agreement grants Elvinix the rights to advance a novel peptide therapy aimed at regenerating and protecting insulin-producing beta cells in patients with type 1 diabetes (T1D). The therapy is designed to be disease-modifying, with the potential to restore insulin secretion, thereby reducing the risk of hypoglycemia and diabetic complications, and lessening the burden of insulin therapy. Elvinix was co-founded by Dr. Alex Rabinovitch, Dr. Jay Skyler, and Dr. Alexander Fleming, experts in diabetes and metabolic medicine. The company is currently in preclinical development and plans to move its lead candidate toward clinical studies, leveraging an extensive package of preclinical data obtained through the licensing agreement.
TrendlineTrendline
GSK Acquires Global Rights to Multiple Myeloma T-Cell Engager from China's Chimagen Biosciences in $750 Million Deal

GSK Acquires Global Rights to Multiple Myeloma T-Cell Engager from China's Chimagen Biosciences in $750 Million Deal

GSK Acquires Global Rights to Multiple Myeloma T-Cell Engager from China's Chimagen Biosciences in $750 Million Deal
Rapid ReadRapid Read
Oncogenomics Revolutionizes Cancer Treatment Decisions Through Genomic Analysis

Oncogenomics Revolutionizes Cancer Treatment Decisions Through Genomic Analysis

Oncogenomics is a specialized field focused on the genomic analysis of tumors to guide cancer treatment decisions. This approach involves studying mutations in oncogenes and tumor suppressor genes, which are critical in the transformation of healthy cells into malignant ones. By understanding these genetic alterations, oncogenomics plays a pivotal role in personalized medicine, allowing for treatments to be tailored to an individual's unique genetic profile. This customization aims to reduce adverse reactions and improve overall healthcare outcomes. The open-access journal Oncotarget actively publishes research across all aspects of oncology, highlighting the ongoing advancements and importance of this field in medical research and practice. Personalized medicine, which includes oncogenomics, has been gaining momentum since the Human Genome Project's completion in 2003, enabling rapid advancements in genetic testing to identify disease-associated mutations.
TrendlineTrendline
Bank of America Increases Stake in Immunic, Inc. by Over 80,000%

Bank of America Increases Stake in Immunic, Inc. by Over 80,000%

Bank of America Increases Stake in Immunic, Inc. by Over 80,000%
Rapid ReadRapid Read
AI Virtual Cell Predicts Personalized Breast Cancer Treatments Using Protein Dynamics

AI Virtual Cell Predicts Personalized Breast Cancer Treatments Using Protein Dynamics

A new AI tool named ProteinTalks has been developed to predict the effectiveness of drugs against cancer cells, identify new drug combinations, and pinpoint proteins linked to drug resistance. This AI virtual cell utilizes protein dynamics by tracking how protein levels shift over time in response to treatment. Researchers captured over 38 million protein measurements from 18 breast cancer cell lines, observing their responses to 63 FDA-approved anticancer drugs and 59 two-drug combinations at various time points (before treatment, 6, 24, and 48 hours). ProteinTalks was trained on this time-resolved dataset, allowing it to learn the dynamic changes in protein levels as drugs take effect. The tool demonstrated superior performance compared to existing AI models based on gene activity and traditional machine-learning methods in predicting drug responses.
TrendlineTrendline
Avacta Announces Board Transition: Mats Blom Appointed Audit Committee Chair as Paul Fry Steps Down

Avacta Announces Board Transition: Mats Blom Appointed Audit Committee Chair as Paul Fry Steps Down

Avacta Announces Board Transition: Mats Blom Appointed Audit Committee Chair as Paul Fry Steps Down